Versantis AG

Address: Technoparkstrasse 1

Sponsor Overview

assignment

Specializations

Hepatic encephalopathy

Versantis AG focuses on overt hepatic encephalopathy in the setting of acute decompensation of liver cirrhosis and acute-on-chronic liver failure, with interest in the neurological and metabolic consequences of impaired liver function.

Hyperammonemia
Acute decompensation of cirrhosis
Standard of care support in encephalopathy

The research activity in this area centers on restoring clinical stability in patients with impaired mental status linked to advanced liver disease.

Acute-on-chronic liver failure

The sponsor also studies ACLF across grades 1, 2, and 3a, reflecting a therapeutic interest in severe liver dysfunction marked by systemic inflammation, organ failure, and high mortality risk.

CLIF-C ACLF score
Hepatic and extrahepatic organ dysfunction
Advanced cirrhosis

This area includes patients with complex disease burden where liver failure intersects with broader physiological decline.

Ascites and abdominal fluid retention

Versantis AG is involved in research addressing ascites in people with acute episodes on top of chronic liver disease, a condition closely associated with worsening portal hypertension and advanced hepatic impairment.

Abdominal fluid accumulation
Decompensated liver disease
Complications of cirrhosis

The therapeutic interest extends to liver-related fluid management alongside neurological and metabolic complications.

Supportive liver disease care

The sponsor’s clinical research spans treatment settings where standard of care is used in patients with severe hepatic illness, with attention to clinically meaningful improvement in liver-related symptoms and disease burden.

Advanced hepatic disease
Metabolic clearance impairment
Neurological complications of liver failure

These studies reflect a concentrated interest in medical conditions arising from progressive liver dysfunction and its systemic effects.

Trial Name	Country	Status
Efficacy and Safety of Intraperitoneal VS-01 with Standard Care in Acute-on-Chronic Liver Failure with Ascites: A Phase 2a Randomized Controlled Study	Belgium France Germany Hungary Italy Spain	Not Recruiting
Evaluation of VS-01 Efficacy and Safety in Overt Hepatic Encephalopathy with Acute Decompensation or ACLF Grade 1: A Phase 2 Randomized Controlled Study	Belgium France Germany Spain	Not Recruiting